Loading
MorphoSys (Novartis)
German antibody company that acquired Constellation's BET inhibitor pelabresib and was itself bought by Novartis in 2024.
Overview
MorphoSys, based in Planegg near Munich, was the German antibody company that developed tafasitamab and acquired Constellation Pharmaceuticals for the BET inhibitor pelabresib, before Novartis bought it in 2024; OnCo marks the record as historic. Tafasitamab, sold as Monjuvi, is a CD19 antibody for diffuse large B-cell lymphoma whose rights moved to Incyte, and pelabresib, acquired with Constellation in 2021, was studied in myelofibrosis in the MANIFEST-2 trial. OnCo links it to diffuse large B-cell lymphoma, to CD19 as a target, to epigenetic drugs and monoclonal antibodies, and to Novartis. Whether pelabresib justifies the price Novartis paid is the question that outlived the company. Tafasitamab has its own page.
Headquarters
Planegg, DE
Scorecard
All companies#187of 1244 companies, score 31
- approved products +6
- targets +2
- modalities +2
- regions +5
- 24-month regulatory events +2
- registry trials +14
1 approved, 0 in phase 3, 0 earlier, 1 targets, 49 registry studies. Formula on the scorecards page.
Deals
Deal map| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2024-02-05 | MorphoSys (Novartis) to Novartis Pelabresib (BET inhibitor) and tulmimetostat | Acquisition | not disclosed | €2.7bn | source |
Type
Website
ApprovedMonoclonal antibody (anti-CD19, Fc-enhanced)
Tafasitamab · Monjuvi
A CD19 antibody given with lenalidomide for lymphoma patients who cannot have a transplant; in 2026 it showed the first frontline gain over R-CHOP in high-risk disease.
Similar pages
- TrialSafety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients
Shares Tafasitamab, Monoclonal antibodies, Diffuse large B-cell lymphoma.
- TrialStudy to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (
Shares Tafasitamab, Monoclonal antibodies, Diffuse large B-cell lymphoma.
- TrialfrontMIND
Shares Tafasitamab, Monoclonal antibodies, Diffuse large B-cell lymphoma.
- TrialTo Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL
Shares Tafasitamab, Monoclonal antibodies, Diffuse large B-cell lymphoma.
- TrialExtension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab
Shares Tafasitamab, Monoclonal antibodies.
- TreatmentPelabresib
Shares MANIFEST-2, Novartis.
- TrialA Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Pa
Shares Tafasitamab, CD19, Monoclonal antibodies.
- PersonChristopher R. Vakoc
Shares Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
cancers
fronts
technologies
targets
drugs
ApprovedMonoclonal antibody (anti-CD19, Fc-enhanced)
Tafasitamab · Monjuvi